Skip to main content

Table 1 Body weight and fasting plasma levels of lipids, glucose and insulin of LDLr−/− mice treated with pravastatin for 3, 6 and 10 months

From: Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice

  3 months 6 months 10 months
Control Pravastatin Control Pravastatin Control Pravastatina
Body weight (g) 19.6 ± 0.4 (6) 19.17 ± 0.3 (6) 22.47 ± 0.2 (6) 22.05 ± 0.7 (6) 23.00 ± 0.3 (5) 21.55 ± 0.4 (4)*
Cholesterol (mg/dL) 584.6 ± 37.5 (6) 324.8 ± 28.6 (6)* 506.5 ± 22.8 (6) 272.0 ± 15.8 (6)* 514.7 ± 32.1 8 (5) 361.1 ± 46.7 (4)*
Triglycerides (mg/dL) 209.3 ± 44.7 (5) 148.4 ± 23.5 (5) 145.0 ± 17.1 (6) 124.9 ± 19.4 (6) 188.4 ± 22.2 (5) 108.1 ± 13.0 (4)*
Glucose (mg/dL) 89.20 ± 4.7 (6) 77.46 ± 3.4 (6) 96.3 ± 3.0 (6) 90.7 ± 4.4 (6) 92.4 ± 3.4 (5) 102.0 ± 6.6 (4)
Insulin (ng/mL) 0.44 ± 0.16 (4) 0.49 ± 0.10(4) 0.42 ± 0.03 (6) 0.45 ± 0.04 (6) 0.39 ± 0.06 (5) 0.33 ± 0.04 (4)
Glucose/insulin 188 ± 41 (4) 172 ± 38 (4) 267 ± 46 (6) 224 ± 27 (6) 258 ± 25 (5) 337 ± 49 (4)
  1. Mean ± SE (n)
  2. * p < 0.05 vs. control (untreated) mice, Student’s t-test
  3. aOne mouse died in the 7th month of treatment. Mice were fasted overnight